HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Aims to achieve CDMO sales of US$ 400 million by 2028
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Strategic focus on COCO-model with a nationwide reach of 501 stores
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Poor oral health (periodontal disease) impacts nearly 51% of Indians
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
